President and Chief Executive Officer
Mr. Atwell has 23 years of drug development and commercialization experience in biotechnology companies as well as global pharmaceutical companies. He co-founded Lux Biosciences and served as its Chief Operating Officer. Previously, as VP of Sales and Marketing at Enzon Pharmaceuticals, he directed the marketing of a diverse specialty product portfolio, including Oncology, Transplantation and Infectious Disease. Mr. Atwell led the successful launch of CellCept at Roche, growing it to the leading immunosuppressive agent in the U.S. transplantation market. At Merck Mr. Atwell was involved in the international launch of COZAAR/HYZAAR and Crixivan.